CA3075872A1 - A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof - Google Patents
A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof Download PDFInfo
- Publication number
- CA3075872A1 CA3075872A1 CA3075872A CA3075872A CA3075872A1 CA 3075872 A1 CA3075872 A1 CA 3075872A1 CA 3075872 A CA3075872 A CA 3075872A CA 3075872 A CA3075872 A CA 3075872A CA 3075872 A1 CA3075872 A1 CA 3075872A1
- Authority
- CA
- Canada
- Prior art keywords
- sleep
- compound
- subject
- administered
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558703P | 2017-09-14 | 2017-09-14 | |
| US62/558,703 | 2017-09-14 | ||
| US201862624680P | 2018-01-31 | 2018-01-31 | |
| US201862624678P | 2018-01-31 | 2018-01-31 | |
| US62/624,678 | 2018-01-31 | ||
| US62/624,680 | 2018-01-31 | ||
| US201862653189P | 2018-04-05 | 2018-04-05 | |
| US62/653,189 | 2018-04-05 | ||
| PCT/US2018/051048 WO2019055764A1 (en) | 2017-09-14 | 2018-09-14 | C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3075872A1 true CA3075872A1 (en) | 2019-03-21 |
Family
ID=65723895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3075872A Pending CA3075872A1 (en) | 2017-09-14 | 2018-09-14 | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220110949A1 (enExample) |
| EP (2) | EP4218767A1 (enExample) |
| JP (3) | JP2020534270A (enExample) |
| AU (2) | AU2018334214A1 (enExample) |
| CA (1) | CA3075872A1 (enExample) |
| IL (2) | IL303083A (enExample) |
| MX (3) | MX2020002889A (enExample) |
| TW (2) | TW201919642A (enExample) |
| WO (1) | WO2019055764A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2862076C (en) | 2012-01-23 | 2020-04-21 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
| PL2887944T3 (pl) | 2012-08-21 | 2022-02-21 | Sage Therapeutics, Inc. | Allopregnanolon do leczenia lekoopornego stanu padaczkowego |
| MX362543B (es) | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| RS60343B1 (sr) | 2014-11-27 | 2020-07-31 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns-a |
| JOP20190022B1 (ar) | 2016-08-23 | 2023-03-28 | Sage Therapeutics Inc | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN114761019A (zh) * | 2019-12-05 | 2022-07-15 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX362543B (es) * | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. |
| EP4275748A3 (en) * | 2014-10-16 | 2024-01-03 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| JOP20190022B1 (ar) * | 2016-08-23 | 2023-03-28 | Sage Therapeutics Inc | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
-
2018
- 2018-09-14 AU AU2018334214A patent/AU2018334214A1/en not_active Abandoned
- 2018-09-14 WO PCT/US2018/051048 patent/WO2019055764A1/en not_active Ceased
- 2018-09-14 MX MX2020002889A patent/MX2020002889A/es unknown
- 2018-09-14 IL IL303083A patent/IL303083A/en unknown
- 2018-09-14 TW TW107132510A patent/TW201919642A/zh unknown
- 2018-09-14 EP EP23150618.9A patent/EP4218767A1/en active Pending
- 2018-09-14 US US16/647,203 patent/US20220110949A1/en not_active Abandoned
- 2018-09-14 TW TW111150395A patent/TW202339764A/zh unknown
- 2018-09-14 EP EP18786464.0A patent/EP3681510A1/en not_active Withdrawn
- 2018-09-14 JP JP2020514950A patent/JP2020534270A/ja active Pending
- 2018-09-14 CA CA3075872A patent/CA3075872A1/en active Pending
-
2020
- 2020-03-08 IL IL273126A patent/IL273126A/en unknown
- 2020-03-13 MX MX2023010063A patent/MX2023010063A/es unknown
- 2020-03-13 MX MX2023010064A patent/MX2023010064A/es unknown
-
2023
- 2023-01-24 JP JP2023008782A patent/JP2023038310A/ja active Pending
- 2023-03-01 US US18/176,571 patent/US20230201224A1/en not_active Abandoned
-
2024
- 2024-06-05 JP JP2024091642A patent/JP2024107137A/ja active Pending
- 2024-08-07 AU AU2024205601A patent/AU2024205601A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018334214A1 (en) | 2020-03-26 |
| JP2020534270A (ja) | 2020-11-26 |
| MX2023010064A (es) | 2023-09-06 |
| IL303083A (en) | 2023-07-01 |
| TW201919642A (zh) | 2019-06-01 |
| JP2023038310A (ja) | 2023-03-16 |
| AU2024205601A1 (en) | 2024-08-29 |
| WO2019055764A1 (en) | 2019-03-21 |
| JP2024107137A (ja) | 2024-08-08 |
| TW202339764A (zh) | 2023-10-16 |
| MX2020002889A (es) | 2020-10-01 |
| EP4218767A1 (en) | 2023-08-02 |
| IL273126A (en) | 2020-04-30 |
| MX2023010063A (es) | 2023-09-06 |
| EP3681510A1 (en) | 2020-07-22 |
| US20220110949A1 (en) | 2022-04-14 |
| US20230201224A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230201224A1 (en) | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| US10702529B2 (en) | Compositions and methods for treating insomnia | |
| US20230192612A1 (en) | Formulations of t-type calcium channel modulators and methods of use thereof | |
| JP2018184440A (ja) | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 | |
| US20230165847A1 (en) | Methods of use of t-type calcium channel modulators | |
| JP2016074728A (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| US20250387414A1 (en) | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| US20250295646A1 (en) | Methods of use of t-type calcium channel modulators | |
| HK40096830A (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| US20220305012A1 (en) | Lemborexant for treating sleep issues | |
| RU2844395C2 (ru) | Лемборексант для лечения проблем со сном | |
| US20250375380A1 (en) | High strength single unit dose formulations and methods of use thereof | |
| CN102341103A (zh) | 贝特类的新用途 | |
| EP3989976A1 (en) | Lemborexant for treating sleep issues | |
| WO2020263331A1 (en) | Lemborexant for treating sleep issues | |
| AU2024238367A1 (en) | Method for treating l-dopa-induced dyskinesia using befiradol | |
| JP2025514644A (ja) | 痙縮を治療するための化合物及び方法 | |
| HK1145282B (en) | Treatment of sleep disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230912 |